Stocks · News reference
Morgan Stanley analyst Ricky Goldwasser maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $300 to $340.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical
The global synthetic antibody library market is projected to grow from $1.63 billion in 2025 to $2.86 billion by 2030, representing a 12% CAGR. Growth is driven by AI-integrated antibody design, increased demand for therapeutic antibodies, high-throughput screening technologies, and expansion of contract research organizations. North America leads the market while Asia-Pacific shows fastest growth potential.
The global animal model market is projected to grow from USD 2.02 billion in 2025 to USD 3.31 billion by 2034, expanding at a CAGR of 5.46%. Growth is driven by rising pharmaceutical research, CRISPR-Cas9 advances, personalized medicine demand, and vaccine R&D expansion. Rodents remain the dominant animal type, while key players include Charles River Laboratories, Eurofins Scientific, and The Jackson Laboratory.